7151 Safety and treatment (trx) patterns of multikinase inhibitors (MKI) in patients (pts) with metastatic renal cell carcinoma (mRCC) in Italy
Pamela Di Cesare(Policlinico San Matteo Fondazione), M.S. Duh, K. Chen, Chiara Paglino, Elisa Ferraris(Fondazione Salvatore Maugeri), Ilaria Imarisio(University of Pavia), Lucia Antràs, Camillo Porta(University of Pavia), M. Neary, Angioletta Lasagna(University of Pavia)
Cited by 0
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275